Shareholder voteRegulatory filing
What was reported
On May 27, 2026, DexCom, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business on April 1, 2026, the record date for the Annual Meeting, there were 385,872,977 shares of Dexcom’s common stock, $0.001 par value per share, outstanding and entitled to vote. 336,525,352 shares were present in person or represented by proxy at the Annual Meeting, which constituted a quorum for the transaction of business.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · May 28, 2026 · Open the source ↗
What the evidence supports
Dexcom told the SEC (Form 8-K, Item 5.07) that its shareholders voted on matters put to them, and what the outcome was. The filing gives May 27, 2026 as the date of the earliest event reported.
What remains unknown
How individual shareholders voted, and what the company will do next beyond what it disclosed.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.07 textOn May 27, 2026, DexCom, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business on April 1, 2026, the record date for the Annual Meeting, there were 385,872,977 shares of Dexcom’s common stock, $0.001 par value per share, outstanding and entitled to vote. 336,525,352 shares were present in person or represented by proxy at the Annual Meeting, which constituted a quorum for the transaction of business.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · May 28, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Dexcom reports results of a shareholder vote (Form 8-K, Item 5.07)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.